Full Press Release Details
Virtual Bell Potter Healthcare Conference, November 18, 2024
Jefferies London Healthcare Conference, November 19, 2024
MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.
Conference details are as follows:
| Bell Potter Healthcare Conference | |
| Presentation: | Monday, November 18, 2024, 3:00 PM AEDT (Virtual) |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com . |
| Jefferies London Healthcare Conference 2024 | |
| One-on-One Meetings: | Tuesday, November 19, 2024 |
| Participant: | Frederic Guerard, PharmD, CEO, Opthea |
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
LifeSci Advisors, LLC
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited